4571.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:15):

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan...

Stats
Today's Volume	253 300
Average Volume	544 349
Market Cap	12.46B
EPS	¥0 ( 2024-02-13 )
Next earnings date	( ¥0 ) 2024-05-10
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-11.86
ATR14	¥0.479 (0.27%)

Volume Correlation

Long: 0.09 (neutral)

Short: 0.49 (neutral)

Signal:(53.882) Neutral

NanoCarrier Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NanoCarrier Co., Ltd. Correlation - Currency/Commodity

-0.02
( neutral )

0.45
( neutral )

0.00
( neutral )

-0.47
( neutral )

-0.44
( neutral )

0.44
( neutral )

NanoCarrier Co., Ltd. Financials

Annual	2022
Revenue:	¥202.19M
Gross Profit:	¥159.60M (78.94 %)
EPS:	¥-18.70

Q3	2023
Revenue:	¥13.20M
Gross Profit:	¥11.79M (89.32 %)
EPS:	¥-3.70

Q2	2023
Revenue:	¥32.20M
Gross Profit:	¥24.21M (75.19 %)
EPS:	¥-2.73

Q1	2023
Revenue:	¥58.91M
Gross Profit:	¥50.98M (86.55 %)
EPS:	¥-4.07

Financial Reports:

No articles found.

NanoCarrier Co., Ltd.

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.